Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miricorilant in MASH
NCT06947304Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of miricorilant in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Corcept Therapeutics. Primary endpoints: Change in fasting hepatic lipogenesis at 6 weeks and Change in peak lipogenesis at 6 weeks. Started Aug 2025; status: completed.
02
Drugs
miricorilant
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT06947304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06947304.